North America’s new essential meeting for Cell & Gene leaders.
The race to commercialize cell & gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market.
With so few treatments on the market to benchmark against, and a relatively unknown understanding of the long-term patient journey, the industry knows it has huge challenges to overcome.
It’s not good enough to sell patients and physicians on the dream. We must forge the way alongside government and payers to build new reimbursement models, and scale manufacturing with the optimal patient journey at the centre. All of this while continuing to identify new patient populations to ensure long-term commercial success.
Reuters Events’ Cell & Gene Therapy Conference will bring together every key stakeholder to define commercialization approaches and get your solution to patients faster.
Kelly Page, Head of Global Cell Therapy Commercialization, Takeda Oncology
Both in-house innovation as well as mutually beneficial, strategic partnerships are essential to bringing transformative cell therapies to patients efficiently. Takeda is unafraid to take the road less traveled when it looks more promising for patients and I’m speaking at Reuters Events Cell & Gene Therapy USA 2020 to encourage others to do the same.
